Covered recipient · General Payments record
BRIAN A COSTELL
Allopathic & Osteopathic Physicians Psychiatry & Neurology Epilepsy
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2021 · Entire year
$107,770.70
419 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2021 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $98,467.31 | 72 |
| Food and Beverage | $7,394.77 | 343 |
| Honoraria | $1,500.00 | 1 |
| Travel and Lodging | $367.12 | 2 |
| Education | $41.50 | 1 |
By paying entity
PY2021 · entire year · sorted by reported total
Page 2 of 9; records 51–100 of 419 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
BRIAN A COSTELL
NPI 1174563688 · CMS profile ID 766906
Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Epilepsy
BOCA RATON, FL
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 9; records 51–100 of 419 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1174563688?year=2021&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- BRIAN A COSTELL, NPI 1174563688, CMS profile ID 766906. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 9; records 51–100 of 419 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1174563688?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- APA 7
- IndustryPayments. (2026). BRIAN A COSTELL, NPI 1174563688, CMS profile ID 766906. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 9; records 51–100 of 419 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1174563688?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- Bluebook
- BRIAN A COSTELL, NPI 1174563688, CMS profile ID 766906, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 9; records 51–100 of 419 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1174563688?year=2021&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2021
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30
419 matching records · $107,770.70 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–100 of 419.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| AbbVie Inc. | $2.97 | 11/09/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 794290697 | CMS |
| Biogen, Inc. | $15.59 | 11/09/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 827827995 | CMS |
| MITSUBISHI TANABE PHARMA AMERICA, INC. | $20.50 | 11/05/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 844026667 | CMS |
| Sunovion Pharmaceuticals Inc. | $18.62 | 11/04/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 821700635 | CMS |
| Amgen Inc. | $18.48 | 11/03/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 825189109 | CMS |
| Amgen Inc. | $7.34 | 11/02/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 825189105 | CMS |
| SK Life Science, Inc. | $22.54 | 11/02/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 826826517 | CMS |
| UPSHER-SMITH LABORATORIES LLC | $14.40 | 11/02/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 834702081 | CMS |
| AbbVie Inc. | $1,440.00 | 11/01/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 794290693 | CMS |
| CATALYST PHARMACEUTICALS, INC. | $95.72 | 10/29/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 828334063 | CMS |
| Lilly USA, LLC | $700.00 | 10/29/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 818899363 | CMS |
| Lilly USA, LLC | $350.00 | 10/29/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 818980509 | CMS |
| AbbVie Inc. | $97.29 | 10/28/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 794290689 | CMS |
| AbbVie Inc. | $2,400.00 | 10/28/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 794290691 | CMS |
| Eisai Inc. | $17.03 | 10/28/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 818017023 | CMS |
| Mallinckrodt Hospital Products Inc. | $28.09 | 10/28/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 845351715 | CMS |
| Allergan, Inc. | $15.86 | 10/26/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 792741885 | CMS |
| Biogen, Inc. | $14.17 | 10/26/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 827828003 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $4.29 | 10/26/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 819899999 | CMS |
| AbbVie Inc. | $1.07 | 10/25/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 794290687 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $1.56 | 10/25/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 819899997 | CMS |
| Acorda Therapeutics, Inc | $17.24 | 10/22/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 792552481 | CMS |
| Allergan, Inc. | $18.17 | 10/22/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 792741883 | CMS |
| Celgene Corporation | $10.99 | 10/22/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 783732323 | CMS |
| SK Life Science, Inc. | $19.19 | 10/15/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 826826505 | CMS |
| Teva Pharmaceuticals USA, Inc. | $4.75 | 10/14/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 839501911 | CMS |
| AbbVie Inc. | $1.20 | 10/13/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 794290683 | CMS |
| AbbVie Inc. | $0.75 | 10/13/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 794290685 | CMS |
| Abbott Laboratories | $137.52 | 10/13/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 815752435 | CMS |
| EMD Serono, Inc. | $18.38 | 10/13/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 849144501 | CMS |
| Amneal Pharmaceuticals LLC | $13.05 | 10/12/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 829651083 | CMS |
| Lilly USA, LLC | $700.00 | 10/12/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 818991493 | CMS |
| AbbVie Inc. | $13.46 | 10/11/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 794290681 | CMS |
| AbbVie Inc. | $1,750.00 | 10/08/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 794290679 | CMS |
| CSL Behring | $20.00 | 10/08/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 820198993 | CMS |
| Novartis Pharmaceuticals Corporation | $21.63 | 10/08/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 812645417 | CMS |
| Grifols USA, LLC | $19.02 | 10/06/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 846782969 | CMS |
| Amneal Pharmaceuticals LLC | $121.20 | 10/05/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 829651079 | CMS |
| GENZYME CORPORATION | $240.00 | 10/05/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 843515749 | CMS |
| Lilly USA, LLC | $350.00 | 10/05/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 818987951 | CMS |
| Octapharma USA, Inc. | $13.62 | 10/05/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 812973711 | CMS |
| Sunovion Pharmaceuticals Inc. | $14.97 | 10/04/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 821819177 | CMS |
| UPSHER-SMITH LABORATORIES LLC | $14.63 | 10/01/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 834697389 | CMS |
| HARMONY BIOSCIENCES LLC | $34.43 | 09/29/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 853078787 | CMS |
| Lilly USA, LLC | $700.00 | 09/29/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 818980505 | CMS |
| AbbVie Inc. | $2.83 | 09/28/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 794290677 | CMS |
| Merz Pharmaceuticals, LLC | $21.76 | 09/27/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 845431745 | CMS |
| CATALYST PHARMACEUTICALS, INC. | $1,500.00 | 09/25/2021 | Honoraria | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 828332461 | CMS |
| Alfasigma USA, Inc. | $17.10 | 09/24/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 853045953 | CMS |
| Biogen, Inc. | $11.43 | 09/24/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 827828001 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $857,870.90 | 51 |
| PY2024 | Principal investigator | $731,660.39 | 67 |
| PY2023 | Recipient | $43,517.60 | 10 |
| PY2023 | Principal investigator | $574,879.61 | 46 |
| PY2022 | Recipient | $6,643.00 | 3 |
| PY2022 | Principal investigator | $768,996.83 | 30 |
| PY2021 | Recipient | $7,591.95 | 2 |
| PY2021 | Principal investigator | $209,112.46 | 23 |
| PY2020 | Recipient | $6,463.00 | 1 |
| PY2020 | Principal investigator | $218,655.09 | 25 |
| PY2019 | Recipient | $40,339.01 | 5 |
| PY2019 | Principal investigator | $136,491.05 | 27 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
51 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | ABBVIE INC. | $811.92 | 12/31/2025 | Non-covered Recipient Entity PHYSICIANS GROUP SERVICES PA | A Phase 2 Multicenter, Randomized, Double-blind, Placebo-controlled Study of BOTOX (Botulinum Toxin Type A) Purified Neurotoxin Complex for the Treatment of Upper Limb Essential Tremor | No dispute reported | 06/30/2026 | 1202534343 |
| Principal investigator 1 | ABBVIE INC. | $600.00 | 12/31/2025 | Non-covered Recipient Entity FIRST CHOICE NEUROLOGY | A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Ubrogepant for the Preventive Treatment of Menstrual Migraine with an Open-Label Extension | No dispute reported | 06/30/2026 | 1202534345 |
| Principal investigator 1 | ABBVIE INC. | $1,854.00 | 12/31/2025 | Non-covered Recipient Entity FIRST CHOICE NEUROLOGY | A Phase 3 Multicenter 24-Week Open-Label Study to Evaluate the Safety, Tolerability, and Efficacy of Atogepant When Added to OnabotulinumtoxinA (BOTOX) for the Preventive Treatment of Chronic Migraine | No dispute reported | 06/30/2026 | 1202534347 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $152,506.25 | 12/24/2025 | Non-covered Recipient Entity Neurology Offices Of South Florida PLLC | Safety/Tolerability of Xanomeline/Trospium (X/T) on Cognition in Participants with Alzheimers Disease | No dispute reported | 06/30/2026 | 1235995421 |
| Principal investigator 1 | Ipsen Innovation | $2,000.00 | 12/12/2025 | Non-covered Recipient Entity Neurology Offices South Florida | A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults | No dispute reported | 06/30/2026 | 1184288686 |
| Principal investigator 1 | Ipsen Innovation | $3,000.00 | 12/12/2025 | Non-covered Recipient Entity Neurology Offices South Florida | A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults | No dispute reported | 06/30/2026 | 1184288688 |
| Principal investigator 1 | Ipsen Innovation | $1,000.00 | 12/12/2025 | Non-covered Recipient Entity Neurology Offices South Florida | A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults | No dispute reported | 06/30/2026 | 1184288690 |
| Principal investigator 1 | Ipsen Innovation | $10,000.00 | 12/12/2025 | Non-covered Recipient Entity Neurology Offices South Florida | A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults | No dispute reported | 06/30/2026 | 1184288692 |
| Principal investigator 1 | Ipsen Innovation | $1,000.00 | 12/12/2025 | Non-covered Recipient Entity Neurology Offices South Florida | A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults | No dispute reported | 06/30/2026 | 1184288694 |
| Principal investigator 1 | Ipsen Innovation | $3,000.00 | 12/12/2025 | Non-covered Recipient Entity Neurology Offices South Florida | A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults | No dispute reported | 06/30/2026 | 1184288696 |
| Principal investigator 1 | Ipsen Innovation | $1,000.00 | 12/12/2025 | Non-covered Recipient Entity Neurology Offices South Florida | A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults | No dispute reported | 06/30/2026 | 1184288698 |
| Principal investigator 1 | ABBVIE INC. | $10,126.35 | 12/04/2025 | Non-covered Recipient Entity NEUROLOGY OFFICES OF S FL PLLC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202527818 |
| Principal investigator 1 | ARGENX US, INC. | $1,500.00 | 11/18/2025 | Non-covered Recipient Entity NEUROLOGY OFFICES OF SOUTH FLORIDA | A randomized, double-blinded, placebo-controlled, phase 3, parallel group design study evaluating the efficacy and safety of efgartigimod IV in adult participants with acetylcholine receptor binding antibody (AChR-Ab) seronegative generalized myasthenia gravis (gMG). | No dispute reported | 06/30/2026 | 1237154510 |
| Principal investigator 1 | ABBVIE INC. | $7,357.50 | 11/05/2025 | Non-covered Recipient Entity NEUROLOGY OFFICES OF S FL PLLC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202522433 |
| Principal investigator 1 | PFIZER INC. | $17,775.67 | 10/23/2025 | Non-covered Recipient Entity NEUROLOGY OFFICES OF SOUTH FLORIDA PLLC | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIMEGEPANT IN EPISODIC MIGRAINE PREVENTION WITH MULTIPLE DOSING REGIMENS | No dispute reported | 06/30/2026 | 1228737884 |
| Principal investigator 1 | ABBVIE INC. | $29,948.40 | 10/09/2025 | Non-covered Recipient Entity NEUROLOGY OFFICES OF S FL PLLC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202514757 |
| Principal investigator 1 | Ipsen Innovation | $383.47 | 09/25/2025 | Non-covered Recipient Entity Neurology Offices South Florida | A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults | No dispute reported | 06/30/2026 | 1184288682 |
| Principal investigator 1 | Ipsen Innovation | $126.00 | 09/25/2025 | Non-covered Recipient Entity Neurology Offices South Florida | A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults | No dispute reported | 06/30/2026 | 1184288684 |
| Principal investigator 1 | ABBVIE INC. | $147.68 | 09/23/2025 | Non-covered Recipient Entity NEUROLOGY OFFICES OF S FL PLLC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202511920 |
| Principal investigator 1 | Eli Lilly and Company | $2,900.00 | 08/25/2025 | Non-covered Recipient Entity NEUROLOGY OFFICES OF SOUTH FLORIDA, PLLC | ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF LY3372689 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE | No dispute reported | 06/30/2026 | 1187884400 |
| Principal investigator 1 | ARGENX US, INC. | $598.00 | 08/19/2025 | Non-covered Recipient Entity NEUROLOGY OFFICES OF SOUTH FLORIDA | A Long-Term, Single Arm, Open-Label, Multicenter, Phase 3 Study to Evaluate the Safety and Tolerability of Multiple Subcutaneous Injections of Efgartigimod PH20 SC in Patients With Generalized Myasthenia Gravis. | No dispute reported | 06/30/2026 | 1237154500 |
| Principal investigator 1 | ARGENX US, INC. | $10,418.40 | 08/19/2025 | Non-covered Recipient Entity NEUROLOGY OFFICES OF SOUTH FLORIDA | A Long-Term, Single Arm, Open-Label, Multicenter, Phase 3 Study to Evaluate the Safety and Tolerability of Multiple Subcutaneous Injections of Efgartigimod PH20 SC in Patients With Generalized Myasthenia Gravis. | No dispute reported | 06/30/2026 | 1237154503 |
| Principal investigator 1 | ARGENX US, INC. | $25,645.75 | 08/19/2025 | Non-covered Recipient Entity NEUROLOGY OFFICES OF SOUTH FLORIDA | A Long-Term, Single Arm, Open-Label, Multicenter, Phase 3 Study to Evaluate the Safety and Tolerability of Multiple Subcutaneous Injections of Efgartigimod PH20 SC in Patients With Generalized Myasthenia Gravis. | No dispute reported | 06/30/2026 | 1237154507 |
| Principal investigator 1 | ABBVIE INC. | $1,854.00 | 08/18/2025 | Non-covered Recipient Entity NEUROLOGY OFFICES OF S FL PLLC | Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine | No dispute reported | 06/30/2026 | 1202505025 |
| Principal investigator 1 | ABBVIE INC. | $2,925.45 | 07/02/2025 | Non-covered Recipient Entity NEUROLOGY OFFICES OF S FL PLLC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202496605 |
| Principal investigator 1 | ABBVIE INC. | $2,925.45 | 06/03/2025 | Non-covered Recipient Entity NEUROLOGY OFFICES OF S FL PLLC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202488341 |
| Principal investigator 1 | ARGENX US, INC. | $13,000.00 | 05/22/2025 | Non-covered Recipient Entity NEUROLOGY OFFICES OF SOUTH FLORIDA | A randomized, double-blinded, placebo-controlled, phase 3, parallel-group design study evaluating the efficacy and safety of efgartigimod PH20 SC administered by prefilled syringe in adult participants with ocular myasthenia gravis | No dispute reported | 06/30/2026 | 1237154519 |
| Principal investigator 1 | Celgene Corporation | $11,571.13 | 05/21/2025 | Non-covered Recipient Entity Neurology Offices Of South Florida PLLC | A Multicenter, Longitudinal, Open-Label, Single-Arm Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated with Ozanimod (RPC-1063) | No dispute reported | 06/30/2026 | 1222306211 |
| Principal investigator 1 | ARGENX US, INC. | $2,200.00 | 05/08/2025 | Non-covered Recipient Entity NEUROLOGY OFFICES OF SOUTH FLORIDA | A randomized, double-blinded, placebo-controlled, phase 3, parallel group design study evaluating the efficacy and safety of efgartigimod IV in adult participants with acetylcholine receptor binding antibody (AChR-Ab) seronegative generalized myasthenia gravis (gMG). | No dispute reported | 06/30/2026 | 1237154481 |
| Principal investigator 1 | ABBVIE INC. | $7,492.50 | 05/07/2025 | Non-covered Recipient Entity NEUROLOGY OFFICES OF S FL PLLC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202482715 |
| Principal investigator 1 | PFIZER INC. | $3,465.30 | 04/24/2025 | Non-covered Recipient Entity NEUROLOGY OFFICES OF SOUTH FLORIDA PLLC | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIMEGEPANT IN EPISODIC MIGRAINE PREVENTION WITH MULTIPLE DOSING REGIMENS | No dispute reported | 06/30/2026 | 1228763589 |
| Principal investigator 1 | ARGENX US, INC. | $280.00 | 04/15/2025 | Non-covered Recipient Entity NEUROLOGY OFFICES OF SOUTH FLORIDA | A Long-Term, Single Arm, Open-Label, Multicenter, Phase 3 Study to Evaluate the Safety and Tolerability of Multiple Subcutaneous Injections of Efgartigimod PH20 SC in Patients With Generalized Myasthenia Gravis. | No dispute reported | 06/30/2026 | 1237154486 |
| Principal investigator 1 | ARGENX US, INC. | $1,200.00 | 04/15/2025 | Non-covered Recipient Entity NEUROLOGY OFFICES OF SOUTH FLORIDA | A Long-Term, Single Arm, Open-Label, Multicenter, Phase 3 Study to Evaluate the Safety and Tolerability of Multiple Subcutaneous Injections of Efgartigimod PH20 SC in Patients With Generalized Myasthenia Gravis. | No dispute reported | 06/30/2026 | 1237154491 |
| Principal investigator 1 | ARGENX US, INC. | $600.00 | 04/15/2025 | Non-covered Recipient Entity NEUROLOGY OFFICES OF SOUTH FLORIDA | A Long-Term, Single Arm, Open-Label, Multicenter, Phase 3 Study to Evaluate the Safety and Tolerability of Multiple Subcutaneous Injections of Efgartigimod PH20 SC in Patients With Generalized Myasthenia Gravis. | No dispute reported | 06/30/2026 | 1237154493 |
| Principal investigator 1 | ARGENX US, INC. | $1,360.00 | 04/15/2025 | Non-covered Recipient Entity NEUROLOGY OFFICES OF SOUTH FLORIDA | A Long-Term, Single Arm, Open-Label, Multicenter, Phase 3 Study to Evaluate the Safety and Tolerability of Multiple Subcutaneous Injections of Efgartigimod PH20 SC in Patients With Generalized Myasthenia Gravis. | No dispute reported | 06/30/2026 | 1237154497 |
| Principal investigator 1 | ABBVIE INC. | $3,678.75 | 04/03/2025 | Non-covered Recipient Entity NEUROLOGY OFFICES OF S FL PLLC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202473385 |
| Principal investigator 1 | ABBVIE INC. | $3,775.00 | 03/10/2025 | Non-covered Recipient Entity NEUROLOGY OFFICES OF SOUTH FLORIDA PLLC | M21-307 - Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine | No dispute reported | 06/30/2026 | 1202462200 |
| Principal investigator 1 | ABBVIE INC. | $4,050.00 | 03/07/2025 | Non-covered Recipient Entity NEUROLOGY OFFICES OF S FL PLLC | M23-714 - Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202461685 |
| Principal investigator 1 | ABBVIE INC. | $300.00 | 02/27/2025 | Non-covered Recipient Entity NEUROLOGY OFFICES OF S FL PLLC | M22-418 - Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine | No dispute reported | 06/30/2026 | 1202454309 |
| Principal investigator 1 | ABBVIE INC. | $1,008.00 | 02/27/2025 | Non-covered Recipient Entity NEUROLOGY OFFICES OF S FL PLLC | M22-418 - Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine | No dispute reported | 06/30/2026 | 1202454313 |
| Principal investigator 1 | ABBVIE INC. | $2,925.00 | 02/27/2025 | Non-covered Recipient Entity NEUROLOGY OFFICES OF S FL PLLC | M22-418 - Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine | No dispute reported | 06/30/2026 | 1202454375 |
| Principal investigator 1 | ABBVIE INC. | $4,726.35 | 02/06/2025 | Non-covered Recipient Entity NEUROLOGY OFFICES OF S FL PLLC | M23-714 - Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202447242 |
| Principal investigator 1 | ABBVIE INC. | $1,000.00 | 02/05/2025 | Non-covered Recipient Entity NEUROLOGY OFFICES OF S FL PLLC | M22-418 - Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine | No dispute reported | 06/30/2026 | 1202444294 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $4,892.69 | 01/27/2025 | Non-covered Recipient Entity First Choice Neurology | A Randomized, Double-blind, Placebo-controlled, Global Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986446, an Anti-MTBR Tau Monoclonal Antibody, in Participants with Early Alzheimers Disease (TargetTau-1) | No dispute reported | 06/30/2026 | 1235997395 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $156,811.50 | 01/16/2025 | Non-covered Recipient Entity First Choice Neurology | A Randomized, Double-blind, Placebo-controlled, Global Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986446, an Anti-MTBR Tau Monoclonal Antibody, in Participants with Early Alzheimers Disease (TargetTau-1) | No dispute reported | 06/30/2026 | 1235997393 |
| Principal investigator 1 | Eli Lilly and Company | $28.95 | 01/09/2025 | Non-covered Recipient Entity NEUROLOGY OFFICES OF SOUTH FLORIDA, PLLC | ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF LY3372689 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE | No dispute reported | 06/30/2026 | 1187885906 |
| Principal investigator 1 | ABBVIE INC. | $1,485.86 | 01/02/2025 | Non-covered Recipient Entity NEUROLOGY OFFICES OF S FL PLLC | M22-418 - Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine | No dispute reported | 06/30/2026 | 1202433949 |
| Principal investigator 1 | ABBVIE INC. | $3,127.95 | 01/02/2025 | Non-covered Recipient Entity NEUROLOGY OFFICES OF S FL PLLC | M23-714 - Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202433953 |
| Principal investigator 1 | ARGENX US, INC. | $87.69 | 01/02/2025 | Non-covered Recipient Entity NEUROLOGY OFFICES OF SOUTH FLORIDA | A randomized, double-blinded, placebo-controlled, phase 3, parallel group design study evaluating the efficacy and safety of efgartigimod IV in adult participants with acetylcholine receptor binding antibody (AChR-Ab) seronegative generalized myasthenia gravis (gMG). | No dispute reported | 06/30/2026 | 1237154515 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $178,710.76 | 01/01/2025 | Non-covered Recipient Entity FIRST CHOICE NEUROLOGY | An Open label Single Arm Multi center Extension Study Evaluating Long term Safety Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis | No dispute reported | 06/30/2026 | 1190302137 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $158,689.18 | 01/01/2025 | Non-covered Recipient Entity NEUROLOGY OFFICES OF SOUTH FLORIDA PLLC | A randomized, double-blind, placebo-controlled phase III study to evaluate the efficacy, safety, and tolerability of iptacopan in patients with generalized Myasthenia Gravis (gMG), followed by an open label extension phase | No dispute reported | 06/30/2026 | 1190308580 |